- Home
- DIBS vs DRUG Comparison
DIBS vs DRUG Comparison
Compare DIBS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- DRUG
- Stock Information
- Founded
- DIBS 2000
- DRUG 2019
- Country
- DIBS United States
- DRUG United States
- Employees
- DIBS N/A
- DRUG N/A
- Industry
- DIBS Catalog/Specialty Distribution
- DRUG Pharmaceuticals and Biotechnology
- Sector
- DIBS Consumer Discretionary
- DRUG Health Care
- Exchange
- DIBS Nasdaq
- DRUG Nasdaq
- Market Cap
- DIBS 175.8M
- DRUG 210.7M
- IPO Year
- DIBS 2021
- DRUG N/A
- Fundamental
- Price
- DIBS $3.92
- DRUG $32.38
- Analyst Decision
- DIBS Buy
- DRUG
- Analyst Count
- DIBS 1
- DRUG 0
- Target Price
- DIBS $8.00
- DRUG N/A
- AVG Volume (30 Days)
- DIBS 107.8K
- DRUG 382.4K
- Earning Date
- DIBS 11-08-2024
- DRUG 11-26-2024
- Dividend Yield
- DIBS N/A
- DRUG N/A
- EPS Growth
- DIBS N/A
- DRUG N/A
- EPS
- DIBS N/A
- DRUG N/A
- Revenue
- DIBS $86,409,000.00
- DRUG N/A
- Revenue This Year
- DIBS $5.82
- DRUG N/A
- Revenue Next Year
- DIBS $7.96
- DRUG N/A
- P/E Ratio
- DIBS N/A
- DRUG N/A
- Revenue Growth
- DIBS N/A
- DRUG N/A
- 52 Week Low
- DIBS $3.65
- DRUG $0.93
- 52 Week High
- DIBS $6.30
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- DIBS 40.48
- DRUG 43.69
- Support Level
- DIBS $3.65
- DRUG $36.02
- Resistance Level
- DIBS $4.16
- DRUG $44.70
- Average True Range (ATR)
- DIBS 0.14
- DRUG 5.79
- MACD
- DIBS -0.02
- DRUG -3.22
- Stochastic Oscillator
- DIBS 36.49
- DRUG 6.26
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company's single reportable and operating segment contains two reporting units; 1stDibs, which consists of the company's online marketplace that enables commerce between sellers and buyers; and Design Manager, which is the company's separate online platform that is used to sell a software solution to interior designers. It generates revenue primarily from fees from seller marketplace services as well as other services, including advertisements and software services.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.